| IVD Diagnostic Molecule Raw Enzymes Market Forecast to Grow at 7.13% CAGR by 2034 |
Globe Newswire |
12/15 |
09:00 |
| Pro Music Rights and Music Licensing, Inc. Announce Potential Antitrust and Defamation Actions in Response to Mischaracterizations by Congressman Scott Fitzgerald and Industry Lobby Groups |
Globe Newswire |
12/11 |
17:02 |
| Rabbet Launches Central Inbox to Eliminate Document Chaos for Real Estate Developers |
Globe Newswire |
12/09 |
08:03 |
| ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment |
Globe Newswire |
12/08 |
19:45 |
| ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP |
Globe Newswire |
12/08 |
19:45 |
| ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% |
Globe Newswire |
12/08 |
19:45 |
| Aeries Technology Demonstrates 60% AP Processing Acceleration with AI-Powered Invoice Automation |
Globe Newswire |
12/08 |
08:15 |
| ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances |
Globe Newswire |
12/07 |
20:10 |
| Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting |
Globe Newswire |
12/06 |
10:15 |
| Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA |
Globe Newswire |
12/04 |
19:00 |
| Complete Coverage of the Edward Jones Big 12 Football Championship Game Available on TuneIn |
Globe Newswire |
12/04 |
09:01 |
| TeleSpecialists Welcomes Neurologist Dr. Jessica Lowe, Known to 230,000+ Followers as “Doctor Brain Barbie” |
Globe Newswire |
12/04 |
09:00 |
| Westwood One Scores Savanah Bananas’ Broadcast Entertainer Drake C. Toll to Host Mornings on New 24/7 Sports Talk Lineup |
Globe Newswire |
12/03 |
11:00 |
| EXP expands aviation portfolio with design of its 13th air traffic control tower: Begins work at Leesburg Executive Airport |
Globe Newswire |
12/02 |
10:30 |
| NAD Logistics Partners with Lighthouz AI to Automate Invoice Audits and Scale Back-Office Operations |
Globe Newswire |
12/02 |
09:08 |
| Kinetics Invests in and Partners with Amogy to Advance Clean Energy Solutions for Floating Power and Data Center Infrastructure |
Globe Newswire |
12/02 |
08:00 |
| NevGold Intercepts Highest-Grade Oxide Antimony At Bullet Zone Discovery: 5.51% Antimony Over 4.6 Meters Within 4.00 g/t AuEq Over 41.1 Meters (0.96% Antimony And 0.29 g/t Au) at Limo Butte, Nevada |
Globe Newswire |
12/02 |
07:00 |
| Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 |
Globe Newswire |
12/01 |
08:00 |
| CSX Chief Financial Officer and Chief Operating Officer to Address UBS Global Industrials and Transportation Conference |
Globe Newswire |
11/25 |
09:00 |
| Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy |
Globe Newswire |
11/24 |
19:00 |
| Auditoria Named in Top 50 Financial Technology Companies by The Financial Technology Report |
Globe Newswire |
11/24 |
13:12 |
| Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights |
Globe Newswire |
11/22 |
06:25 |
| AP Copilot to Host Official Launch Celebration |
Globe Newswire |
11/20 |
13:23 |
| Crunchafi and Fieldguide Partner to Redefine Audit Efficiency |
Globe Newswire |
11/19 |
09:00 |
| Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 |
Globe Newswire |
11/19 |
08:00 |
